Argininosuccinic Aciduria (ASA) Market Size and Share, Market Trends

Argininosuccinic Aciduria (ASA)

The urea cycle disorders are a group of rare disorders affecting the urea cycle, a series of biochemical processes in which nitrogen is converted into urea and removed from the body through the urine. Nitrogen is a waste product of protein metabolism. Failure to break down nitrogen results in the abnormal accumulation of nitrogen, in the form of ammonia, in the blood. Argininosuccinic aciduria (ASA) is an inherited disorder that causes ammonia to accumulate in the blood. Ammonia, which is formed when proteins are broken down in the body, is toxic if the levels become too high. The nervous system is especially sensitive to the effects of excess ammonia.

DelveInsight's "Argininosuccinic Aciduria (ASA) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Argininosuccinic aciduria (ASA), historical and forecasted epidemiology as well as the Argininosuccinic aciduria (ASA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

 

The Argininosuccinic aciduria (ASA) market report provides current treatment practices, emerging drugs, Argininosuccinic aciduria (ASA) market share of the individual therapies, current and forecasted Argininosuccinic aciduria (ASA) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Argininosuccinic aciduria (ASA) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan

Study Period: 2017-2030

Argininosuccinic Aciduria (ASA) Disease Understanding and Treatment Algorithm

Argininosuccinic aciduria usually becomes evident in the first few days of life. An infant with argininosuccinic aciduria may be lacking in energy (lethargic) or unwilling to eat, and have a poorly controlled breathing rate or body temperature. Some babies with this disorder experience seizures or unusual body movements, or go into a coma. Complications from argininosuccinic aciduria may include developmental delay and intellectual disability. Progressive liver damage, high blood pressure (hypertension), skin lesions, and brittle hair may also be seen.

The DelveInsight Argininosuccinic aciduria (ASA) market report gives a thorough understanding of the Argininosuccinic aciduria (ASA) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Argininosuccinic aciduria (ASA).

Treatment

The treatment of argininosuccinic aciduria is aimed at preventing excessive ammonia from being formed or from removing excessive ammonia during a hyperammonemic episode. Long-term therapy combines dietary restrictions and the stimulation of alternative methods of converting and excreting nitrogen from the body (alternative pathways therapy).

It covers the details of conventional and current medical therapies available in the Argininosuccinic aciduria (ASA) market for the treatment of the condition. It also provides Argininosuccinic aciduria (ASA) treatment algorithms and guidelines in the United States, Europe, and Japan.

Request for sample pages: https://www.delveinsight.com/report-store/argininosuccinic-aciduria-market

Argininosuccinic Aciduria (ASA) Epidemiology 

According to the National Organization for Rare Disorders:

•       Argininosuccinic aciduria is a rare disorder that affects fewer than a thousand people in the United States. It is estimated to affect anywhere between approximately one in 70,000 to 1 in 218,000 live births. Most cases of this condition are detected shortly after birth by newborn screening.

•       Males and females are affected in equal numbers. Onset of symptoms usually occurs at birth, but may not be noticeable for days or weeks. In some children, onset of symptoms may not occur until later during infancy or childhood.

•       The estimated frequency of urea cycle disorders collectively is approximately one in 30,000. However, because urea cycle disorders like argininosuccinic aciduria often go unrecognized, these disorders are under-diagnosed, making it difficult to determine their true frequency in the general population.

The Argininosuccinic aciduria (ASA) epidemiology division provide insights about historical and current Argininosuccinic aciduria (ASA) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Argininosuccinic Aciduria (ASA) Drug Chapters

The current pipeline for Argininosuccinic Aciduria does not hold many significant products.

The dynamics of Argininosuccinic Aciduria market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, increased R&D activities and incremental healthcare spending across  the world.

Drug chapter segment of the Argininosuccinic aciduria (ASA) report encloses the detailed analysis of Argininosuccinic aciduria (ASA) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Argininosuccinic aciduria (ASA) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Argininosuccinic Aciduria (ASA) Market Outlook

Aggressive treatment is needed in hyperammonemic episodes that have progressed to vomiting and increased lethargy. Affected individuals may be hospitalized and protein may be completely eliminated from the diet for 24 hours. Affected individuals may also receive treatment with intravenous administration of arginine and a combination of sodium benzoate and sodium phenylacetate. Non-protein calories may be also provided as glucose.

In individuals where there is no improvement or where hyperammonemic coma develops, the removal of wastes by filtering an affected individual’s blood through a machine (hemodialysis) may be necessary. Hemodialysis is also used to treat infants, children, and adults who are first diagnosed with argininosuccinic aciduria during hyperammonemic coma. In some individuals, a liver transplant may be recommended. This is an option of last resort for specific individuals who have progressive liver disease, experience recurrent medical crises and hospitalizations despite therapy, or who have a poor quality of life.

The factors that shall expedite the growth of Argininosuccinic Aciduria market include increasing awareness about available treatments during the forecast period (2019–2030). Overall, the increasing Incidence, disease awareness, and promising emerging pipeline therapies will propel the market size forward during the forecast period. A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Argininosuccinic Aciduria.

According to DelveInsight, Argininosuccinic aciduria (ASA) market in 7MM is expected to change in the study period 2017-2030.

Request for sample pages: https://www.delveinsight.com/report-store/argininosuccinic-aciduria-market